In Brief: Spine-Tech
This article was originally published in The Gray Sheet
Executive Summary
Spine-Tech: Firm plans controlled worldwide market launch in the fourth quarter of 1997 of its BAK/Proximity implant for use in spinal fusion procedures to treat symptomatic degenerative disc disease following recent marketing clearance from FDA, the firm states. The device, which is intended for use in patients with a small anatomy, differs from the firm's flagship BAK implant in that it features "greater porosity," concave sides, and allows for closer placement between the vertebrae of two implants, one BAK and one BAK/Proximity...
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.